 Today, NGM Biopharmaceuticals Inc NASDAQ: NGM reported disappointing results from the Phase 3 trial of aldafermin in NASH patients. What Happened: The primary endpoint of an improvement in fibrosis with no worsening of NASH among the 107 patients taking a 0.3 mg, 1 mg, or 3 mg dose flopped badly. 